Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 866 entries
View as:

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Phase: N/A Priority: Normal
NCT ID: NCT06834789 Org: User:
Start: 02/18/25 End: 12/31/25 Due: 12/31/26

Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2

Phase: N/A Priority: Normal
NCT ID: NCT02945228 Org: User:
Start: 10/26/16 End: 07/26/19 Due: 07/26/20

A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece

Phase: N/A Priority: Normal
NCT ID: NCT02713295 Org: User:
Start: 06/16/16 End: 04/19/19 Due: 04/19/20

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06332534 Org: User:
Start: 07/26/24 End: 12/31/34 Due: 12/31/35

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04127695 Org: User:
Start: 03/03/20 End: 06/16/20 Due: 06/16/21

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase: N/A Priority: Normal
NCT ID: NCT06291220 Org: User:
Start: 01/27/25 End: 07/31/29 Due: 07/31/30

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05044234 Org: User:
Start: 11/16/21 End: 11/30/22 Due: 11/30/23

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Phase: N/A Priority: Normal
NCT ID: NCT03234712 Org: User:
Start: 10/10/17 End: 04/14/21 Due: 04/14/22

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

Phase: N/A Priority: Normal
NCT ID: NCT06543914 Org: User:
Start: 11/26/24 End: 02/28/29 Due: 02/28/30

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06718101 Org: User:
Start: 12/19/24 End: 05/31/27 Due: 05/31/28

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Phase: N/A Priority: Normal
NCT ID: NCT02243280 Org: User:
Start: 08/31/14 End: 02/29/16 Due: 02/28/17

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03661138 Org: User:
Start: 10/27/18 End: 08/19/22 Due: 08/19/23

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT02023112 Org: User:
Start: 01/31/14 End: 09/30/15 Due: 09/30/16

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Phase: N/A Priority: Normal
NCT ID: NCT03148756 Org: User:
Start: 05/12/17 End: 08/04/17 Due: 08/04/18

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Phase: N/A Priority: Normal
NCT ID: NCT03061812 Org: User:
Start: 04/11/17 End: 02/12/20 Due: 02/12/21

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03706040 Org: User:
Start: 12/27/18 End: 04/26/21 Due: 04/26/22

An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05170646 Org: User:
Start: 03/14/22 End: 01/31/24 Due: 01/31/25

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT02023099 Org: User:
Start: 12/31/13 End: 10/31/15 Due: 10/31/16

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01782495 Org: User:
Start: 02/25/13 End: 07/13/17 Due: 07/13/18

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Phase: N/A Priority: Normal
NCT ID: NCT02066389 Org: User:
Start: 03/26/14 End: 07/02/15 Due: 07/02/16

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Phase: N/A Priority: Normal
NCT ID: NCT02573324 Org: User:
Start: 01/04/15 End: 04/04/22 Due: 04/04/23

BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Phase: N/A Priority: Normal
NCT ID: NCT02047110 Org: User:
Start: 01/28/14 End: 07/25/16 Due: 07/25/17

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06895356 Org: User:
Start: 03/26/25 End: 06/16/25 Due: 06/16/26

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Phase: N/A Priority: Normal
NCT ID: NCT06632951 Org: User:
Start: 01/20/25 End: 08/31/28 Due: 08/31/29

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

Phase: N/A Priority: Normal
NCT ID: NCT05606757 Org: User:
Start: 05/07/24 End: 09/26/25 Due: 09/26/26